Rockwell's Triferic AVNU Receives the US FDA's Approval to Replace Iron and Maintain Hemoglobin Hemodialysis Patients
Shots:
- The approval is based on the study assessing Triferic in adult patients with hemodialysis-dependent chronic kidney disease and has resulted in steady and consistent bioavailable iron to replace the iron that is lost at every dialysis treatment and hemoglobin is maintained
- The company will launch Evaluation Programs for evaluating Triferic and with expected launch in Q3’20
- Triferic AVNU (ferric pyrophosphate citrate) is a IV formulation of Triferic and a novel treatment for iron replacement and maintenance of hemoglobin in hemodialysis patients
Click here to read full press release/ article | Ref: Rockwell | Image: Rockwell
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com